Hypercalcemia as an Immune-Related Adverse Event in a Patient Receiving Nivolumab and Ipilimumab for Metastatic Melanoma: A Case Report
Hypercalcemia of malignancy is a well-known phenomenon in cancer patients, often associated with poor prognosis. The discovery of immune checkpoint inhibitors has revolutionised cancer therapy by improving prognosis in numerous different cancer types. Unfortunately, immune-related adverse events fre...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Case Reports in Oncological Medicine |
| Online Access: | http://dx.doi.org/10.1155/crom/8600200 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|